Patent Invalidation in San Diego.

Patent invalidation San Diego strategy is unusual because the city runs two very different innovation economies at once, and each produces a different kind of patent fight. San Diego is the birthplace of modern cellular technology — Qualcomm invented CDMA here and holds one of the world’s deepest standard-essential patent portfolios — and it is at the same time a global capital of genomics and life sciences, anchored by Illumina and a dense cluster of biotech, diagnostics and medical-device companies. A defendant accused in San Diego is usually fighting either a wireless standard-essential patent or a biotech claim, and the invalidity playbook differs sharply between them. PerspireIP builds litigation-grade prior-art and invalidity searches for both.

Why patent invalidation San Diego cases split between wireless and life sciences

Patent invalidation San Diego work does not have a single profile the way a hardware town or a pharma town might. The region carries two distinct patent economies, and the technology decides everything about how you attack a claim. On one side sits the wireless world Qualcomm built — cellular, RF front-end, modem, power-management and connectivity inventions, many of them declared essential to 3GPP and other standards. On the other sits the life-sciences cluster — DNA sequencing, genomics, diagnostics, antibodies and medical devices — where the decisive question is often whether the claim is even eligible for a patent at all.

These two worlds need opposite search disciplines. A wireless standard-essential patent is usually invalidated with earlier technical contributions, working-group documents and prior specifications; a biotech or diagnostics patent is more often invalidated on eligibility under 35 U.S.C. §101 or on written description and enablement, using the scientific literature. Getting the search strategy right starts with correctly classifying which San Diego fight you are actually in.

• Wireless / telecom — cellular SEPs, RF, modems, connectivity: attack on §102/§103 with standards and technical prior art
• Life sciences — sequencing, genomics, diagnostics, antibodies: attack on §101 eligibility, §112 disclosure and literature prior art
• Defense / dual-use — unmanned systems, sensors, comms: mixed grounds and classified-adjacent prior-art challenges

Where San Diego patent disputes are litigated: the Southern District, the PTAB and the ITC

Most San Diego patent trials are heard in the U.S. District Court for the Southern District of California, which sits in the Edward J. Schwartz and James M. Carter and Judith N. Keep courthouses downtown and covers San Diego and Imperial counties. Because Qualcomm and Illumina are headquartered here, the district has seen landmark technology cases — Qualcomm v. Broadcom over an undisclosed standards patent, and the 2019 Qualcomm v. Apple jury verdict finding several iPhone models infringed Qualcomm patents. The local bench and bar are unusually technical; many San Diego patent litigators hold advanced science and engineering degrees.

District court is not the only forum. Validity can be challenged administratively at the Patent Trial and Appeal Board (PTAB) through inter partes review, and San Diego companies are heavy PTAB users — Illumina, for example, has knocked out competitor and university sequencing patents in a string of IPRs. For imports, the U.S. International Trade Commission runs Section 337 investigations, a forum Qualcomm used repeatedly against Apple. Appeals from all three routes converge on the U.S. Court of Appeals for the Federal Circuit.

• Southern District of California — jury trials, all invalidity grounds available, clear-and-convincing standard
• PTAB (inter partes review) — §102/§103 only, patents and printed publications, preponderance standard
• USITC Section 337 — fast exclusion-order forum for imported products, invalidity raised as a defense

Wireless and cellular SEPs: invalidating patents from the Qualcomm cluster

San Diego is where cellular standards were commercialized, and the patents asserted out of this ecosystem are frequently declared essential to a standard such as 3GPP’s LTE or 5G NR. A standard-essential patent is a double-edged sword for its owner: the very act of declaring it essential means the claimed technique is supposed to be practiced by anyone implementing the standard — which points a defendant straight at the standard’s own development history for invalidating prior art.

The decisive references in a cellular case are rarely limited to issued patents. They live in the technical record produced as the standard evolved: change requests and contribution documents submitted to 3GPP working groups (RAN1, RAN2 and others), earlier releases of the specification itself, ETSI declarations and archives, and academic and conference papers on coding, modulation and radio-resource management. A patent invalidation San Diego search for a wireless SEP has to date each of these to prove public availability before the asserted priority date.

• 3GPP TSG working-group contributions, tdocs and change requests, with meeting dates established
• Superseded specification releases and ETSI standards archives
• IEEE, conference and journal literature on coding, MIMO, scheduling and power control
• Earlier chipset datasheets, reference designs and implementation documentation

Because SEP damages and injunction exposure are large, the quality of this technical prior art often decides whether a defendant settles on FRAND terms or fights validity to the end.

Life sciences and Section 101: biotech and diagnostics eligibility

San Diego’s life-sciences cluster — Illumina in sequencing, plus hundreds of genomics, diagnostics, antibody and device companies around Torrey Pines and Sorrento Valley — produces a completely different kind of invalidity fight. Here the first and often decisive attack is not prior art at all; it is patent eligibility under 35 U.S.C. §101. The Supreme Court’s decisions in Mayo v. Prometheus (2012) and Association for Molecular Pathology v. Myriad Genetics (2013) held that laws of nature, natural phenomena and isolated natural DNA are not patent-eligible, and the two-step Alice/Mayo framework has since invalidated many diagnostic-method and correlation claims.

For a defendant sued over a diagnostic assay, a biomarker correlation or a sequencing method, that means a §101 motion can end the case before prior art is ever weighed. Where a claim survives eligibility, the next pressure points are §112 written description and enablement — a recurring weakness in broadly drafted antibody and genomics claims — and then §102/§103 using the scientific literature, GenBank and sequence databases, protocols, and prior publications by the inventors themselves.

Life-sciences invalidity therefore runs on two clocks at once: an eligibility argument built from case law, and a literature-based prior-art record built for the standard a Southern District judge or a PTAB panel applies. We build both so counsel can lead with whichever is strongest.

The U.S. invalidity grounds every San Diego defendant should map

U.S. law gives a defendant several independent ways to prove a patent should never have issued, and a disciplined invalidity project charts the asserted claims against each. The right combination depends on whether you are fighting a wireless SEP or a biotech claim, but the statutory toolbox is the same.

• §102 — novelty: a single prior-art reference that discloses every claim element anticipates the claim; the core of most wireless-standards challenges
• §103 — obviousness: the claim is an obvious combination of prior art to a person of ordinary skill; the most common ground overall and the only substantive ground allowed in an IPR alongside §102
• §101 — eligibility: the claim covers an abstract idea, law of nature or natural phenomenon; the front-line attack on diagnostics and many software claims, decided in court, not at the PTAB
• §112 — disclosure: the specification fails to provide adequate written description or enablement, or the claims are indefinite; a decisive lever against overbroad antibody and genomics claims

In district court, each ground must be proven by clear and convincing evidence because an issued patent is presumed valid. At the PTAB the burden drops to a preponderance of the evidence, which is one reason IPR is such a popular route — and a reason the underlying prior art has to be genuinely strong to survive appeal to the Federal Circuit.

Three attack routes: IPR, district-court invalidity and ITC Section 337

A San Diego defendant usually chooses among three forums, and the choice is driven by the technology, the grounds and the calendar. Inter partes review at the PTAB is the workhorse for §102 and §103 challenges based on patents and printed publications: it is faster and cheaper than trial, applies the lower preponderance standard, and reaches a final written decision within about 18 months of institution. Its limits matter, though — you cannot raise §101 eligibility or §112 in an IPR, and a petition must generally be filed within one year of being served with the infringement complaint.

District-court invalidity in the Southern District is the only route that reaches every ground, including the §101 eligibility attack that dominates diagnostics cases and the §112 arguments that sink overbroad biotech claims. And where the accused product is imported — as smartphones and chipsets are — the ITC’s Section 337 investigation offers a very fast track to an exclusion order, so a respondent must be ready to prove invalidity on a compressed schedule. Qualcomm’s ITC campaigns against Apple show how central that forum is to San Diego wireless disputes.

These routes often run in parallel, and estoppel rules mean the grounds you raise in an IPR can be lost in later litigation. We scope one prior-art record sized to the forum mix you and your counsel choose, so the same evidence works across the PTAB, the Southern District and the ITC.

How PerspireIP builds a patent invalidation San Diego search

Every engagement starts by classifying the fight — wireless SEP or life sciences — because that determines the databases, the grounds and the experts we search around. We then map the asserted claims element by element, pin the priority date that actually governs each claim, and search against that date rather than the filing date printed on the cover.

• Claim charts aligned to §102, §103, §101 and §112, mapped to your chosen forum
• For wireless: 3GPP/ETSI working-group documents, superseded releases and standards archives, dated for public availability
• For life sciences: scientific literature, sequence and protein databases, protocols and prior inventor publications, plus a §101 eligibility read
• Deep non-patent-literature retrieval and defensible public-availability dating for every reference
• A written invalidity opinion and reference packages ready for the Southern District, the PTAB or the ITC

We work as a specialist search partner alongside your San Diego litigators and patent counsel, deliver to IPR and trial deadlines, and keep every engagement confidential. Whether you are a wireless implementer facing a standard-essential assertion, a genomics or diagnostics company challenging a §101-vulnerable claim, or an international firm running the U.S. front of a global dispute, we scale to fit — a single invalidity search, a multi-patent campaign, or ongoing portfolio support. Send us the patent number and your key dates, and we will scope a patent invalidation San Diego project within one business day.

IP Landscape & Resources in San Diego

Key intellectual-property authorities and venues relevant to San Diego:

• United States Patent and Trademark Office (USPTO) — the federal agency that grants U.S. patents and houses the Patent Trial and Appeal Board
• Patent Trial and Appeal Board (PTAB) — hears inter partes review petitions challenging patent validity on novelty and obviousness
• U.S. District Court for the Southern District of California — the San Diego federal trial court that hears patent infringement and invalidity, from Qualcomm to Illumina
• U.S. International Trade Commission (USITC) — runs Section 337 investigations into imported products, where invalidity is a core defense

Request a Patent Invalidation Search in San Diego

Explore related PerspireIP services: Patent Invalidation · Prior Art Litigation Search · Patent Infringement Analysis.

Frequently Asked Questions